Comparison of the effects of two cholecystokinin-receptor antagonists, loxiglumide and L-364,718, on the pancreatic secretory response to intraduodenal tryptophan in dogs.
BACKGROUND
The aim of the study was to compare the effects of the cholecystokinin (CCK)-receptor antagonists loxiglumide and L-364, 718 on the endogenously stimulated pancreatic exocrine secretion.


METHODS
In six conscious dogs with chronic gastric and pancreatic fistulas we compared the action of different doses of loxiglumide (2.5 to 10.0 mg/kg/h) and L-364, 718 (0.025 to 0.1 mg/kg/h) on the pancreatic secretory response to intraduodenal perfusion of graded loads of tryptophan (0.37-10.0 mmol/ h), given against a background of secretin (20.5 pmol/kg/h intravenously).


RESULTS
Both loxiglumide and L-364, 718 inhibited the secretin-stimulated pancreatic bicarbonate output by up to 47% and 48%, respectively. The pancreatic protein output during secretin was significantly inhibited by all doses of L-364,718 (by 65% to 82%) but not by loxiglumide. All doses of loxiglumide and L-364, 718 abolished the 180-min integrated bicarbonate response to tryptophan. The two higher doses of loxiglumide (5.0-10.0 mg/kg/h) and L-364,718 (0.05-0.1 mg/kg/h) significantly decreased the 180-min integrated response to tryptophan by 59% and 79% (loxiglumide) and by 72% and 97% (L-364, 718). The plasma CCK-like immunoreactivity basally and in response to tryptophan was not significantly altered by loxiglumide or L-364, 718.


CONCLUSIONS
These findings indicate that in dogs 1) the pancreatic bicarbonate response to secretin is augmented by the hormone CCK; 2) L-364, 718 but not loxiglumide decreases pancreatic protein output during secretin; 3) endogenous released CCK is involved in the pancreatic bicarbonate response and is a major mediator of pancreatic protein response to intraduodenal tryptophan; and 4) the release of CCK by intraduodenal tryptophan is not influenced by loxiglumide and L-364, 718.
Niebergall-Roth
E
E
Dept. of Medicine IV (Gastroenterology), University Hospital of Heidelberg, Mannheim, Germany.
Teyssen
S
S
Wetzel
D
D
Hartel
M
M
Beglinger
C
C
Riepl
R L
RL
Singer
M V
MV
D000818:Animals; D001570:Benzodiazepinones / Q000008:administration & dosage / Q000494:pharmacology*; D001639:Bicarbonates / Q000378:metabolism; D002766:Cholecystokinin / Q000378:metabolism / Q000502:physiology; D020109:Devazepide; D004285:Dogs; D004386:Duodenum; D005260:Female; D008297:Male; D010179:Pancreas / Q000187:drug effects* / Q000378:metabolism*; D010477:Perfusion; D011377:Proglumide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors*; D012633:Secretin / Q000494:pharmacology; D012844:Sincalide / Q000037:antagonists & inhibitors*; D014364:Tryptophan / Q000008:administration & dosage*
D001570:Benzodiazepinones; D001639:Bicarbonates; D011949:Receptors, Cholecystokinin; D012633:Secretin; C053737:loxiglumide; D014364:Tryptophan; D002766:Cholecystokinin; D011377:Proglumide; D020109:Devazepide; D012844:Sincalide